LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02186 LUYE PHARMA

Not Yet Opened 02-03 16:08:20

2.700

+0.020

+0.75%

High2.720	Low2.630	Vol16.62M
Open2.720	D1 Closing2.680	Amplitude3.36%
Mkt Cap10.79B	Tradable Cap10.79B	Total Shares4.00B
T/O44.49M	T/O Rate0.42%	Tradable Shares4.00B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02186","market":"HK","secType":"STK","nameCN":"LUYE PHARMA","latestPrice":2.7,"timestamp":1770106100004,"preClose":2.68,"halted":0,"volume":16615500,"delay":0,"changeRate":0.007462686567164185,"floatShares":3995000000,"shares":3995000000,"eps":0.125445,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"02-03 16:08:20","open":2.72,"high":2.72,"low":2.63,"amount":44489382,"amplitude":0.033582,"askPrice":2.7,"askSize":679000,"bidPrice":2.69,"bidSize":102500,"shortable":3,"etf":0,"ttmEps":0.109,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770168600000},"marketStatusCode":0,"adr":0,"listingDate":1404835200000,"exchange":"SEHK","adjPreClose":2.68,"openAndCloseTimeList":[[1770082200000,1770091200000],[1770094800000,1770105600000]],"volumeRatio":1.2109451866130505,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02186","defaultTab":"news","newsList":[{"id":"2606279121","title":"China Cinda Subsidiaries to Inject 285 Million Yuan into Luye Pharma Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2606279121","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606279121?lang=en_us&edition=fundamental","pubTime":"2026-01-27 11:07","pubTimestamp":1769483273,"startTime":"0","endTime":"0","summary":"Two China Cinda Asset Management (HKG:1359) subsidiaries will inject 285 million yuan into Luye Pharma's (HKG:2186) oncology unit, Nanjing Luye Pharmaceutical, according to a Tuesday Hong Kong bourse ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1156","BK1191","BK1606","BK1583","01359","02186"],"gpt_icon":0},{"id":"1141447932","title":"LUYE PHARMA (02186) Shareholder Transfers HK$454 Million Worth of Shares from CCB International Securities to UBS Securities Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=1141447932","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141447932?lang=en_us&edition=fundamental","pubTime":"2026-01-27 08:58","pubTimestamp":1769475499,"startTime":"0","endTime":"0","summary":"Hong Kong stock exchange data reveals that on January 26, a shareholder of LUYE PHARMA (02186) transferred shares from CCB International Securities to UBS Securities Hong Kong Limited. The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","02186","BK1583","BK1191","161027"],"gpt_icon":0},{"id":"1189026194","title":"LUYE PHARMA (02186): Nanjing LUYE Pharma Secures RMB 285 Million Capital Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1189026194","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189026194?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:17","pubTimestamp":1769469466,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced that on January 26, 2026, Shenzhen LUYE, Nanjing Xinshi, Nanjing Xin'an, Ningbo Xinda, and Nanjing LUYE entered into a capital injection agreement. Under this agreement,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1606","02186","BK1583"],"gpt_icon":0},{"id":"1140354691","title":"Luye Pharma (02186) Announces RMB285 Million Capital Injection in Nanjing Luye, Triggering Discloseable and Connected Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=1140354691","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140354691?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:04","pubTimestamp":1769468649,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. (02186) announced that on 26 January 2026, Shenzhen Luye, NJ Xinshi, Nanjing Xinan, Ningbo Cinda, and Nanjing Luye entered into agreements for a capital injection totaling...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"gpt_icon":0},{"id":"2606224170","title":"Luye Pharma - Nanjing Xinan, Ningbo Cinda to Provide Further Capital to Nanjing Luye for Total RMB285 Mln on Jan 26","url":"https://stock-news.laohu8.com/highlight/detail?id=2606224170","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606224170?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:02","pubTimestamp":1769468523,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YR0QQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","02186","BK1191","BK1583"],"gpt_icon":0},{"id":"2606224902","title":"Luye Pharma Completes Transfer of 25% Stake in Nanjing Luye to NJ Xinshi","url":"https://stock-news.laohu8.com/highlight/detail?id=2606224902","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606224902?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:00","pubTimestamp":1769468445,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. has completed the transfer of a 25% equity interest in its subsidiary, Nanjing Luye, to NJ Xinshi. Following the completion of the transaction on 19 January 2026, Nanjing Luye is now owned 75% by Luye Pharma Group and 25% by NJ Xinshi. The company stated that the partnership agreement and related transactions allow the Group to maintain control over the identity of Nanjing Luye’s partner, supporting continuity, governance stability, and alignment of strategic objectives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 26, 2026, and is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL1b7LG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","BK1606","02186"],"gpt_icon":0},{"id":"2606245438","title":"Shandong Boan Biotechnology Transfers 11.99 Million H Shares to Complete Minority Stake Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2606245438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606245438?lang=en_us&edition=fundamental","pubTime":"2026-01-26 22:01","pubTimestamp":1769436073,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co. Ltd. has announced that its controlling shareholder, Luye Pharma Group Ltd., through its wholly-owned subsidiary Shandong Luye Pharmaceutical Co., Ltd., will transfer 11,986,600 H shares of Boan Biotechnology to the Issuer on 27 January 2026. This transfer is part of the completion of a previously announced proposed transfer, in accordance with the terms of a subscription agreement related to Exchangeable Preference Shares. The board of Boan Biotechnology does not expect the transaction to have any material adverse effect on the group’s business operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief v","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDLbl2mT3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186","BK1191","BK1161","BK1606","06955","BK1583"],"gpt_icon":0},{"id":"1127306625","title":"BOAN BIOTECH (06955): Shandong Luye Pharmaceutical Plans Further Transfer of 38.5 Million H Shares to Luye Geneora Holding","url":"https://stock-news.laohu8.com/highlight/detail?id=1127306625","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127306625?lang=en_us&edition=fundamental","pubTime":"2026-01-21 22:14","pubTimestamp":1769004855,"startTime":"0","endTime":"0","summary":"The Board of Directors of BOAN BIOTECH (06955) has been notified by its controlling shareholder, LUYE PHARMA Group, that, pursuant to the terms of a subscription agreement related to exchangeable...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186","06955","BK1191","BK1606","BK1161","BK1583"],"gpt_icon":0},{"id":"2605488308","title":"Shandong Boan Biotechnology Transfers 38.5 Million H Shares to New Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2605488308","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605488308?lang=en_us&edition=fundamental","pubTime":"2026-01-21 22:06","pubTimestamp":1769004367,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co. Ltd. announced that its controlling shareholder, Luye Pharma Group Ltd., through its wholly-owned subsidiary Shandong Luye Pharmaceutical Co., Ltd., will transfer 38,500,000 H Shares of Shandong Boan Biotechnology to the Issuer on January 22, 2026. This transfer is part of a previously disclosed arrangement under a subscription agreement related to Exchangeable Preference Shares. The board of Shandong Boan Biotechnology does not expect the transaction to have any material adverse effect on the company’s business operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Ser","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL9pWGGv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","BK1606","BK1583","BK1191","02186","BK1161"],"gpt_icon":0},{"id":"2603628910","title":"A Look At Luye Pharma Group (SEHK:2186) Valuation After Ruoxinlin NDA Acceptance For Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2603628910","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603628910?lang=en_us&edition=fundamental","pubTime":"2026-01-15 02:51","pubTimestamp":1768416671,"startTime":"0","endTime":"0","summary":"Luye Pharma Group (SEHK:2186) is in focus after Chinese regulators accepted a New Drug Application for a new Ruoxinlin indication targeting Generalized Anxiety Disorder, supported by Phase III data in a large patient population.\nSee our latest analysis for Luye Pharma Group.\nThe NDA news has arrived after a mixed period for Luye Pharma Group. The 30 day share price return is 5.99%, while the 90 day share price return shows a 16.16% decline. The 1 year total shareholder return of 49.75%...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/a-look-at-luye-pharma-group-sehk2186-valuation-after-ruoxinl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/a-look-at-luye-pharma-group-sehk2186-valuation-after-ruoxinl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","02186","BK1191","BK1606","BK1583"],"gpt_icon":0},{"id":"2603619976","title":"Shandong Boan Biotechnology Signs Finance Lease Agreement with Industrial Bank Financial Leasing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603619976","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603619976?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:31","pubTimestamp":1768397502,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co. Ltd. has entered into a new finance lease agreement with Industrial Bank Financial Leasing on January 14, 2026. Under the agreement, Industrial Bank Financial Leasing will purchase and lease certain machinery and equipment to Shandong Boan Biotechnology. The company stated that the terms of the finance lease agreement were reached after arm's length negotiations and are considered fair and reasonable. This new agreement is separate from a previous finance lease agreement signed between the two parties in January 2025, which involved different assets. The arrangement is expected to support Shandong Boan Biotechnology’s business activities and strategic goals in both domestic and international markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL45nxNW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000181138.USD","HK0000181112.HKD","BK1191","LU1580142542.USD","BK1606","BK1161","LU1328615791.USD","02186","LU0572940350.SGD","BK0183","BK0028","LU0821914370.USD","601166","BK0012","LU0572939691.SGD","LU1048596156.SGD","BK0278","BK0015","BK1583","LU1781817850.SGD","LU0264606111.USD","06955","BK0187","BK0188"],"gpt_icon":0},{"id":"1100402703","title":"LUYE PHARMA (02186): NDA for New Indication of Class 1 Innovative Drug Ruoxinlin® for Generalized Anxiety Disorder Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1100402703","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100402703?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:11","pubTimestamp":1767870695,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has formally accepted the New Drug Application (NDA) for a new...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186","BK1161","159992","BK1574","BK1191","BK1583","BK1606","06978"],"gpt_icon":0},{"id":"2601531363","title":"Luye Pharma - New Drug Application for Class 1 Innovative Drug Ruoxinlin for New Indication of Generalized Anxiety Disorder Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2601531363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601531363?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:01","pubTimestamp":1767870063,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90EG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1583","BK1606","02186"],"gpt_icon":0},{"id":"2601635263","title":"China Accepts Luye Pharma's NDA for Ruoxinlin in Generalized Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2601635263","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601635263?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:00","pubTimestamp":1767870058,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. has announced that the Centre for Drug Evaluation of the National Medical Products Administration in China has accepted the New Drug Application for a new indication of Ruoxinlin  for the treatment of Generalized Anxiety Disorder. This application marks a significant milestone for Ruoxinlin, which was previously approved in November 2022 for the treatment of Major Depressive Disorder.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL8kXCYC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","BK1606","02186"],"gpt_icon":0},{"id":"1102671099","title":"Luye Pharma (02186): Xia Lian Appointed as Member of Nomination Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=1102671099","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102671099?lang=en_us&edition=fundamental","pubTime":"2025-12-31 19:10","pubTimestamp":1767179417,"startTime":"0","endTime":"0","summary":"Luye Pharma (02186) announced that Ms. Xia Lian, an independent non-executive director of the company, has been appointed as a member of the company's Nomination Committee, effective from December 31, 2025.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02186","BK1606","BK1583"],"gpt_icon":0},{"id":"2595775307","title":"Luye Pharma Appoints Xia Lian to Nomination Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2595775307","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595775307?lang=en_us&edition=fundamental","pubTime":"2025-12-31 19:00","pubTimestamp":1767178834,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. has announced the appointment of Ms. Xia Lian, an independent non-executive director, as a member of its Nomination Committee effective 31 December 2025. Following this change, the Nomination Committee now comprises Professor Lo Yuk Lam , Mr. Zhang Hua Qiao, Mr. Choy Sze Chung Jojo, and Ms. Xia Lian.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 31, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL6fx6ym:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","BK1606","02186"],"gpt_icon":0},{"id":"1195700896","title":"LUYE PHARMA (02186) Grants Exclusive Commercialization Rights for Three Long-Acting Antipsychotic Injections to Enhua in Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=1195700896","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195700896?lang=en_us&edition=fundamental","pubTime":"2025-12-24 17:12","pubTimestamp":1766567545,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced that certain subsidiaries of the group have signed a cooperation agreement with Jiangsu Enhua and Xin Pharmaceutical Marketing Co., Ltd. (Enhua), a subsidiary of Jiangsu...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02186","BK1606","BK1191"],"gpt_icon":0},{"id":"2593782544","title":"Luye Pharma - Certain Units Entered Agreement With Jiangsu Nhwa Hexin Pharmaceutical Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2593782544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593782544?lang=en_us&edition=fundamental","pubTime":"2025-12-24 17:03","pubTimestamp":1766567026,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nFWN3XT0QO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02186","BK1583","BK1191","BK1606"],"gpt_icon":0},{"id":"2593478259","title":"Luye Pharma - Grant of Commercialization Rights to Nhwa for 3 Long-Acting Injectable Antipsychotics in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2593478259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593478259?lang=en_us&edition=fundamental","pubTime":"2025-12-24 17:03","pubTimestamp":1766567026,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nFWN3XT0QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","BK1191","BK1583","02186"],"gpt_icon":0},{"id":"2593784274","title":"Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2593784274","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593784274?lang=en_us&edition=fundamental","pubTime":"2025-12-24 17:01","pubTimestamp":1766566909,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. announced that its subsidiaries have entered into an agreement with Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., Ltd., a subsidiary of Jiangsu Nhwa Pharmaceutical Co., Ltd. Under the agreement, Nhwa is granted exclusive commercialization rights for three long-acting injectable antipsychotics—Rykindo , Ruibailai , and Meibirui —in the Chinese Mainland. The products are indicated for the treatment of schizophrenia. The agreement has a ten-year term, with Nhwa paying a one-time, non-refundable licensing fee of USD 20 million. Luye Pharma will retain product ownership, marketing authorizations, and intellectual property rights, and will remain responsible for manufacturing and supply.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDLbRHJDq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002262","BK0239","LU1064131003.USD","BK0070","BK1606","02186","BK1583","BK0188","LU2148510915.USD","BK1191","LU1064130708.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luye.cn","stockEarnings":[{"period":"1week","weight":-0.069},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.1429},{"period":"6month","weight":-0.2969},{"period":"1year","weight":0.3107},{"period":"ytd","weight":-0.0146}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":0.0188},{"period":"3month","weight":0.0347},{"period":"6month","weight":0.0699},{"period":"1year","weight":0.3273},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Luye Pharma Group Ltd is a company mainly engaged in developing, producing, marketing and selling pharmaceutical products. The Company operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.024212},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019456},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.021667},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.009215},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.0086},{"month":6,"riseRate":0.363636,"avgChangeRate":0.035296},{"month":7,"riseRate":0.636364,"avgChangeRate":0.018026},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.044846},{"month":9,"riseRate":0.583333,"avgChangeRate":0.045957},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00637},{"month":11,"riseRate":0.5,"avgChangeRate":0.024651},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.012685}],"exchange":"SEHK","name":"LUYE PHARMA","nameEN":"LUYE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUYE PHARMA(02186) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUYE PHARMA,02186,LUYE PHARMA股票,LUYE PHARMA股票老虎,LUYE PHARMA股票老虎国际,LUYE PHARMA行情,LUYE PHARMA股票行情,LUYE PHARMA股价,LUYE PHARMA股市,LUYE PHARMA股票价格,LUYE PHARMA股票交易,LUYE PHARMA股票购买,LUYE PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUYE PHARMA(02186) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}